Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 1.52
NYSE:APO's Cash-to-Debt is ranked lower than
71% of the 1516 Companies
in the Global Asset Management industry.

( Industry Median: 9999.00 vs. NYSE:APO: 1.52 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:APO' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.31  Med: 1.52 Max: 116.98
Current: 1.52
1.31
116.98
Equity-to-Asset 0.15
NYSE:APO's Equity-to-Asset is ranked lower than
93% of the 1407 Companies
in the Global Asset Management industry.

( Industry Median: 0.84 vs. NYSE:APO: 0.15 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:APO' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.2  Med: 0.08 Max: 0.15
Current: 0.15
-0.2
0.15
Interest Coverage 18.50
NYSE:APO's Interest Coverage is ranked lower than
72% of the 1341 Companies
in the Global Asset Management industry.

( Industry Median: 1018.62 vs. NYSE:APO: 18.50 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:APO' s Interest Coverage Range Over the Past 10 Years
Min: 7.01  Med: 21.88 Max: 61.24
Current: 18.5
7.01
61.24
Piotroski F-Score: 7
Altman Z-Score: 2.81
Beneish M-Score: -1.57
WACC vs ROIC
7.43%
139.58%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 40.83
NYSE:APO's Operating Margin % is ranked lower than
54% of the 1424 Companies
in the Global Asset Management industry.

( Industry Median: 49.57 vs. NYSE:APO: 40.83 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:APO' s Operating Margin % Range Over the Past 10 Years
Min: -822  Med: 24.32 Max: 582.24
Current: 40.83
-822
582.24
Net Margin % 20.45
NYSE:APO's Net Margin % is ranked lower than
61% of the 1426 Companies
in the Global Asset Management industry.

( Industry Median: 41.12 vs. NYSE:APO: 20.45 )
Ranked among companies with meaningful Net Margin % only.
NYSE:APO' s Net Margin % Range Over the Past 10 Years
Min: -273.16  Med: 10.83 Max: 342.05
Current: 20.45
-273.16
342.05
ROE % 56.05
NYSE:APO's ROE % is ranked higher than
98% of the 1518 Companies
in the Global Asset Management industry.

( Industry Median: 5.44 vs. NYSE:APO: 56.05 )
Ranked among companies with meaningful ROE % only.
NYSE:APO' s ROE % Range Over the Past 10 Years
Min: -196.11  Med: 8.7 Max: 52.27
Current: 56.05
-196.11
52.27
ROA % 7.99
NYSE:APO's ROA % is ranked higher than
72% of the 1548 Companies
in the Global Asset Management industry.

( Industry Median: 2.89 vs. NYSE:APO: 7.99 )
Ranked among companies with meaningful ROA % only.
NYSE:APO' s ROA % Range Over the Past 10 Years
Min: -24.04  Med: 0.86 Max: 7.91
Current: 7.99
-24.04
7.91
ROC (Joel Greenblatt) % 5143.08
NYSE:APO's ROC (Joel Greenblatt) % is ranked higher than
94% of the 912 Companies
in the Global Asset Management industry.

( Industry Median: 45.26 vs. NYSE:APO: 5143.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:APO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -6492.55  Med: 295.13 Max: 5627.12
Current: 5143.08
-6492.55
5627.12
3-Year Revenue Growth Rate -25.80
NYSE:APO's 3-Year Revenue Growth Rate is ranked lower than
83% of the 1012 Companies
in the Global Asset Management industry.

( Industry Median: 1.10 vs. NYSE:APO: -25.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:APO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -30.5 Max: 89.5
Current: -25.8
0
89.5
3-Year EBITDA Growth Rate -30.30
NYSE:APO's 3-Year EBITDA Growth Rate is ranked lower than
84% of the 849 Companies
in the Global Asset Management industry.

( Industry Median: 2.30 vs. NYSE:APO: -30.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:APO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -52.8 Max: 570.6
Current: -30.3
0
570.6
3-Year EPS without NRI Growth Rate -19.40
NYSE:APO's 3-Year EPS without NRI Growth Rate is ranked lower than
74% of the 766 Companies
in the Global Asset Management industry.

( Industry Median: 3.80 vs. NYSE:APO: -19.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:APO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -16.65 Max: 69.3
Current: -19.4
0
69.3
GuruFocus has detected 5 Warning Signs with Apollo Global Management LLC $NYSE:APO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:APO's 10-Y Financials

Financials (Next Earnings Date: 2017-07-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

APO Guru Trades in Q2 2016

Richard Pzena 381,650 sh (+69.36%)
Howard Marks 353,842 sh (unchged)
Tom Gayner 387,000 sh (unchged)
Chuck Royce 656,100 sh (unchged)
» More
Q3 2016

APO Guru Trades in Q3 2016

Tom Gayner 387,000 sh (unchged)
Howard Marks 353,842 sh (unchged)
Chuck Royce 623,400 sh (-4.98%)
Richard Pzena 348,100 sh (-8.79%)
» More
Q4 2016

APO Guru Trades in Q4 2016

Jim Simons 15,334 sh (New)
Tom Gayner 387,000 sh (unchged)
Howard Marks Sold Out
Richard Pzena 333,800 sh (-4.11%)
Chuck Royce 449,200 sh (-27.94%)
» More
Q1 2017

APO Guru Trades in Q1 2017

Tom Gayner 420,000 sh (+8.53%)
» More
» Details

Insider Trades

Latest Guru Trades with APO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Apollo Global Management LLC

SymbolPriceYieldDescription
APOPRA25.430.00

Business Description

Industry: Asset Management » Asset Management    NAICS: 523920    SIC: 6282
Compare:OTCPK:SHNWF, OTCPK:TGOPY, NYSE:AMG, OTCPK:KNVKF, NYSE:KKR, OTCPK:HRGLF, OTCPK:EXXRF, NYSE:IVZ, NAS:SEIC, NAS:ARCC, NYSE:OAK, OTCPK:IGIFF, NYSE:VOYA, OTCPK:GBLBF, OTCPK:RMGOF, NAS:CG, OTCPK:PGPHF, OTCPK:CIFAF, NYSE:EV, OTCPK:IVTJF » details
Traded in other countries:AG31.Germany,
Headquarter Location:USA
Apollo Global Management LLC along with its subsidiaries operates as an alternative asset management company. It raises, invests & manages private equity, credit & real estate funds as well as strategic investment accounts, on behalf of it clients.

Apollo Global Management is a global alternative-asset manager with about $190 billion in assets under management deployed across private equity, credit, and real estate strategies. Apollo also manages AUM for Athene, a fixed-annuity provider, which provides Apollo with a $70 billion-plus source of permanent capital.

Top Ranked Articles about Apollo Global Management LLC

Tiger Global Management Invests in Apollo Global Management Firm buys 361,800 shares
Tiger Global Management, a 10% owner of Apollo Global Management LLC (NYSE:APO), purchased 361,800 shares of Apollo between March 30 and April 4 in three separate transactions according to an SEC filing. Read more...
Presidio, Inc. Announces Pricing of Initial Public Offering

NEW YORK, March 09, 2017 (GLOBE NEWSWIRE) -- Presidio, Inc. (“Presidio”) announced today the pricing of its initial public offering of 16,666,666 shares of its common stock at a price to the public of $14.00 per share. In addition, Presidio has granted the underwriters a 30-day option to purchase an additional 2,499,999 shares. The shares are expected to begin trading on the NASDAQ Global Select Stock Market on March 10, 2017 under the ticker symbol “PSDO.”
The offering is expected to close on or about March 15, 2017, subject to customary closing conditions. J.P. Morgan and Citigroup acted as joint book-running managers for the offering and representatives of the underwriters. Barclays and RBC Capital Markets also acted as joint book-running managers for the offering. Credit Suisse, Goldman, Sachs & Co., Wells Fargo Securities and Evercore ISI acted as book-running managers for the offering. Guggenheim Securities, Apollo Global Securities and LionTree acted as co-managers for the offering. This offering is being made only by means of a prospectus. A copy of the prospectus relating to the offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, toll-free: (866) 803-9204, email: [email protected]; and Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717,  telephone: (800) 831-9146. A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Presidio Presidio is a leading IT solutions provider assisting clients as they harness technology innovation and simplify IT complexity to digitally transform their businesses and drive return on IT investment. Our Digital Infrastructure, Cloud and Security solutions enable our approximately 7,000 middle market, enterprise and government clients to take advantage of new digital revenue streams, omnichannel customer experience models, and the rich data insights generated by those interactions. We deliver this technology expertise through a full life-cycle model of professional, managed, and ongoing support services, including strategy, consulting, design and implementation. Through over 60 US offices and over 2,800 professionals, including approximately 1,600 technical engineers, we are trusted advisors to our clients on a local level while also bringing our national scale and expertise to bear. We had $2.7 billion in annual revenue in fiscal 2016 and are majority owned by funds affiliated with Apollo Global Management, LLC (:APO). Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995  This press release contains “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The use of words such as "anticipates,” “expects,” “intends,” “plans” and “believes,” among others, generally identify forward-looking statements. These forward-looking statements include statements relating to: the completion and timing of the offering, future financial performance, business prospects and strategy, anticipated trends, prospects in the industries in which our businesses operate and other similar matters. These forward looking statements are based on management's current expectations and assumptions about future events, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict. Actual results could differ materially from those contained in these forward looking statements for a variety of reasons, including, among others: risks and uncertainties related to the capital markets, changes in senior management at Presidio, changes in our relationship with our vendor partners, adverse changes in economic conditions, risks resulting from a decreased demand for Presidio’s information technology solutions, risks relating to rapid technological change in Presidio’s industry and risks relating to acquisitions or regulatory changes. Certain of these and other risks and uncertainties are discussed in Presidio’s filings with the Securities and Exchange Commission. Other unknown or unpredictable factors that could also adversely affect our business, financial condition and results of operations may arise from time to time. In light of these risks and uncertainties, these forward looking statements may not prove to be accurate. Accordingly, you should not place undue reliance on these forward looking statements, which only reflect the views of our management as of the date of this press release. We do not undertake to update these forward-looking statements. Source: Presidio, Inc.
Contact Information:

Taylor Watson
Brunswick Group
[email protected]
415-671-7676

Investor Relations
866-232-3762
[email protected]

Read more...
Acasti Announces Grant of Stock Options

LAVAL, QUEBEC--(Marketwired - May 30, 2016) - Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ:ACST)(TSX VENTURE:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia, announces the grant of 310,400 stock options under its Stock Option Plan to its employees, including 200,000 to the Chairman of the Board and 61,400 to the officers. Each option will vest gradually over a period of 3 years (1/3 per year) and will allow its holder to acquire one class A common share of the Company at a price of $1.99 until May 29, 2023. About Acasti Pharma Inc.
Acasti is an emerging biopharmaceutical company focused on the research and development of a prescription drug candidate, CaPre®, for the treatment of severe hypertriglyceridemia, a condition characterized by abnormally high levels of triglycerides in the bloodstream. CaPre® is a krill oil-derived mixture of polyunsaturated fatty acids (PUFAs), primarily composed of omega-3 fatty acids, principally eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) present as a combination of phospholipid esters and free fatty acids. Krill is a major source of phospholipids and omega-3 fatty acids well known to be beneficial for human health. Forward Looking Statements
Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. securities laws and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Acasti to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement and the "Cautionary Note Regarding Forward-Looking Information" section contained in Acasti's latest Annual Information Form, which also forms part of Acasti's latest annual report on Form 20-F, and which is available on SEDAR at www.sedar.com, on EDGAR at www.sec.gov/edgar.shtml and on the investor section of Acasti's website at acastipharma.com (the "AIF"). All forward-looking statements in this press release are made as of the date of this press release. Acasti does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in Acasti's public securities filings with the Securities and Exchange Commission and the Canadian securities commissions. Additional information about these assumptions and risks and uncertainties is contained in the AIF under "Risk Factors". Neither NASDAQ, the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.





Acasti Contact:
Mario Paradis
VP and CFO
1.450.687.2262
[email protected]
www.acastipharma.com




Read more...
Acasti Announces Fourth Quarter and Fiscal Year Results

LAVAL, QUEBEC--(Marketwired - May 25, 2016) - Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ:ACST)(TSX VENTURE:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia, announces its operating and financial results for the fourth quarter and fiscal year ended February 29, 2016. All amounts are in Canadian dollars. "As announced recently, we are delighted with the arrival of our new CEO next week, Ms. Jan D'Alvise's. With her experience and caliber, we believe she will provide strong leadership to Acasti as we exploit the full potential of CaPre, our first product for hypertriglyceridemia," said Dr. Roderick Carter, Acasti's Chairman. On December 16, 2015, Acasti announced that it had made important progress in its correspondence with the US Food and Drug Administration (FDA) regarding next steps in the development plans for CaPre®. "As planned, we initiated and recently completed subject enrollment for the bioavailability bridging study," highlighted Pierre Lemieux, PhD, Acasti's Chief Operating Officer. "We are expecting results of the study before the end of the year which should confirm our chosen regulatory pathway." Fourth Quarter Financial Results

Revenues were $21,000 for the quarter ended February 29, 2016, versus $178,000 for the quarter ended

February 28, 2015
Research and development (R&D) expenses were $1,829,000 for the quarter, down from $2,343,000 in the quarter last year
Non-IFRS operating loss(1) was $1,163,000 for the quarter, versus $2,263,000 in the quarter last year
Net loss was $1,919,000 or $0.18 loss per share for the quarter, versus a net loss of $2,311,000 or $0.21 loss per share in the quarter last year

R&D expenses were lower for the current quarter in comparison with last year largely due to delays in some contract expenses related to Acasti's clinical trials partly offset by an impairment of intangible asset. The year-over-year decline in Non-IFRS operating loss was largely due to lower R&D expenses. Fiscal Year Financial Results

Revenues were $38,000 for the fiscal year ended February 29, 2016, versus $271,000 for the year ended February 28, 2015
Research and development expenses were $7,389,000 for the year, down from $8,857,000 in the prior year
Non-IFRS operating loss was $6,569,000 for the year, versus $8,506,000 in the prior year
A net loss of $6,317,000 or $0.59 loss per share was recorded for the year, versus a net loss of $1,655,000 or $0.16 loss per share in the prior year.

(1) See comment on Non-IFRS operating loss which follows The year-over-year variances for the fiscal year are mainly attributable to the same factors highlighted above for the three-months ended February 29, 2016. Cashflows Cash and short-term investment were $12.5 million as at February 29, 2016 of which $2 million was considered as restricted short-term investment. CaPre® Development Plan As previously announced, Acasti intends to pursue the regulatory pathway for CaPre® under section 505(b)(2)(2) of the Federal Food, Drug, and Cosmetic Act. In conjunction with this, Acasti has recently submitted an amendment to its original FDA Investigational New Drug (IND) application to commence a pivotal bioavailability bridging study, comparing CaPre® to an omega-3 prescription drug as a means of establishing a scientific bridge between the two. The bridging study will help determine the feasibility of a 505(b)(2) regulatory pathway, while also optimizing the protocol design of a Phase 3 trial. The 505(b)(2) approval pathway has been used by many other companies and Acasti's regulatory and clinical experts believe such a strategy is best for CaPre®. This should allow the Corporation to further optimize the advancement of CaPre®, while benefiting most importantly from the substantial clinical and nonclinical data already available with another FDA-approved omega-3 prescription drug. In addition, it should reduce the expected expenses and streamline the overall CaPre® development program required to support a New Drug Application (NDA) submission. (2) See note on "505(b)(2) Regulatory Pathway" 505(b)(2) Regulatory Pathway The 505(b)(2) regulatory pathway is defined in The Federal Food Drug and Cosmetics Act as a New Drug Application (NDA) containing investigations of safety and effectiveness that are being relied upon for approval and were not conducted by or for the applicant, and for which the applicant has not obtained a right of reference. These applications differ from the typical NDA (described under Section 505(b)(1) of the Act), in that they allow a sponsor to rely, at least in part, on the FDA's findings of safety and/or effectiveness for a previously approved drug. Caution Regarding Non-IFRS Financial Measures The Corporation uses adjusted financial measures, including Non-IFRS operating loss (Loss from operating activities before interest, taxes, depreciation and amortization and impairment loss), to assess its operating performance. These non-IFRS financial measures are directly derived from the Company's financial statements and are presented in a consistent manner. The Company uses these measures for the purposes of evaluating its historical and prospective financial performance, as well as its performance relative to competitors. These measures also help the Company to plan and forecast for future periods as well as to make operational and strategic decisions. The Company believes that providing this information to investors, in addition to IFRS measures, allows them to see the Company's results through the eyes of management, and to better understand its historical and future financial performance.

Securities regulations require that companies caution readers that earnings and other measures adjusted to a basis other than IFRS do not have standardized meanings and are unlikely to be comparable to similar measures used by other companies. Accordingly, they should not be considered in isolation. The Corporation uses Non-IFRS operating loss to measure its performance from one period to the next without the variation caused by certain adjustments that could potentially distort the analysis of trends its operating performance, and because the Corporation believes it provides meaningful information on the Corporation's financial condition and operating results. Acasti's method for calculating Non-IFRS operating loss may differ from that used by other corporations. Acasti obtains its Non-IFRS operating loss measurement by adding to net loss, finance costs, depreciation and amortization, impairment loss and income taxes and by subtracting finance income. Finance income/costs include foreign exchange gain (loss) and change in fair value of derivatives. Acasti also excludes the effects of certain non-monetary transactions recorded, such as stock-based compensation, from its Non-IFRS operating loss calculation. The Corporation believes it is useful to exclude this item as it is a non-cash expense. Excluding this item does not imply it is necessarily nonrecurring. About Acasti Pharma Inc. Acasti is an emerging biopharmaceutical company focused on the research and development of a prescription drug candidate, CaPre®, for the treatment of severe hypertriglyceridemia, a condition characterized by abnormally high levels of triglycerides in the bloodstream. CaPre® is a krill oil-derived mixture of polyunsaturated fatty acids (PUFAs), primarily composed of omega-3 fatty acids, principally eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) present as a combination of phospholipid esters and free fatty acids. Krill is a major source of phospholipids and omega-3 fatty acids well known to be beneficial for human health. Forward Looking Statements Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. securities laws and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Acasti to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement and the "Cautionary Note Regarding Forward-Looking Information" section contained in Acasti's latest Annual Information Form, which also forms part of Acasti's latest annual report on Form 20-F, and which is available on SEDAR at www.sedar.com, on EDGAR at www.sec.gov/edgar.shtml and on the investor section of Acasti's website at acastipharma.com (the "AIF"). All forward-looking statements in this press release are made as of the date of this press release. Acasti does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in Acasti's public securities filings with the Securities and Exchange Commission and the Canadian securities commissions. Additional information about these assumptions and risks and uncertainties is contained in the AIF under "Risk Factors". Neither NASDAQ, the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.





Acasti Contact:
Mario Paradis
VP and CFO
1.450.687.2262
[email protected]
www.acastipharma.com




Read more...
Jan D'Alvise Appointed President & CEO of Acasti Pharma

Seasoned Executive in Drug Development

LAVAL, QUEBEC--(Marketwired - May 12, 2016) - Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ:ACST)(TSX VENTURE:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia, has appointed Ms. Jan D'Alvise as President and Chief Executive Officer effective June 1, 2016. Acasti's new Board of Directors will be elected at the next annual general meeting of shareholders scheduled for July 12, 2016. Ms. D'Alvise has been nominated to join the Board. Ms. D'Alvise is an accomplished executive with experience in large, public multi-national companies, as well as in private start-ups in the life sciences industry. Her exceptional track-record includes leadership roles across the enterprise life-cycle, from start-up to commercialization and growth. Ms. D'Alvise has established strategic partnerships of substantial value and secured significant financing through institutional investors. "We are delighted to introduce someone of Jan D'Alvise's experience and caliber. We believe she will provide strong leadership to Acasti as we exploit the full potential of CaPre, our first product for hypertriglyceridemia," said Dr. Roderick Carter, Acasti's Chairman. "This is a big step forward in Acasti's plans to succeed as an emerging pharma company. Insightful and determined leadership is key. We have valued the interim strategic guidance of Neptune's Chairman Pierre Fitzgibbon as an Acasti Director. Mr. Fitzgibbon will not stand for re-election at the upcoming AGM, but his experience has been invaluable during this transition. Together, we will nominate a strong slate of directors to support Jan in her new role." "I believe in the enormous potential of our technology to improve therapies for millions of patients around the world suffering from hypertriglyceridemia," said Ms. D'Alvise. "I am impressed with the passion and dedication of our employees, and am honored to have been chosen by the Board to lead the Acasti team. I am deeply committed to building long-term value for patients, clinicians, and our shareholders." Subject to the TSX Venture Exchange (TSXV) and shareholder approval at the Corporation's next annual and special meeting, the Board of Directors amended the existing stock option plan in order to raise the current limit of shares reserved for issuance under the plan and approved the grant of options to Ms. D'Alvise to purchase 525,000 common shares of the Corporation at a strike price per option equal to $1.56 CAN. Subject to the terms and conditions of the Corporation's stock option plan, vesting of the award will occur on an equal quarterly basis over a three (3) year term and expire after seven (7) years. About Jan D'Alvise Ms. D'Alvise has extensive experience in diagnostics, medical devices, pharmaceuticals and drug discovery research tools. Until recently, Ms. D'Alvise was the President and Chairman of Pediatric Bioscience. Before that, she was the CEO of Gish Biomedical, a cardiopulmonary medical device company. Prior to Gish, Ms. D'Alvise was the CEO of the Sidney Kimmel Cancer Center (SKCC), a drug discovery research institute. From 1995, she was also the Co-Founder and Executive VP/COO of Metrika Inc., and in 1999 was the Co-Founder/President/CEO/ Chairman of NuGEN, Inc. Ms. D'Alvise built both companies from technology concept through to successful regulatory approvals, product introduction and sustainable revenue growth.
Prior to 1995, Ms. D'Alvise was a VP of Drug Development at Syntex/Roche and Business Unit Director of their Pain and Inflammation business, and also VP of Commercial Operations at SYVA, (Syntex's clinical diagnostics division), and began her career with Diagnostic Products Corporation (DPC). Ms. D'Alvise has a B.S. in Biochemistry from Michigan Technological University. She has completed post-graduate work at the University of Michigan, Stanford University, and the Wharton Business Schools. Jan has served on the board of numerous private companies and non-profits, and is an Entrepreneur-in-Residence for the von Liebig Institute for Entrepreneurship at the University of California, San Diego. About Acasti Pharma Inc. Acasti is an emerging biopharmaceutical company focused on the research and development of a prescription drug candidate, CaPre®, for the treatment of severe hypertriglyceridemia, a condition characterized by abnormally high levels of triglycerides in the bloodstream. CaPre® is a krill oil-derived mixture of polyunsaturated fatty acids (PUFAs), primarily composed of omega-3 fatty acids, principally eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) present as a combination of phospholipid esters and free fatty acids. Krill is a major source of phospholipids and omega-3 fatty acids well known to be beneficial for human health. Forward Looking Statements Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. securities laws and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Acasti to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement and the "Cautionary Note Regarding Forward-Looking Information" section contained in Acasti's latest Annual Information Form, which also forms part of Acasti's latest annual report on Form 20-F, and which is available on SEDAR at www.sedar.com, on EDGAR at www.sec.gov/edgar.shtml and on the investor section of Acasti's website at acastipharma.com (the "AIF"). All forward-looking statements in this press release are made as of the date of this press release. Acasti does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in Acasti's public securities filings with the Securities and Exchange Commission and the Canadian securities commissions. Additional information about these assumptions and risks and uncertainties is contained in the AIF under "Risk Factors". Neither NASDAQ, the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.





Mario Paradis
Chief Financial Officer
1.450.687.2262
[email protected]
www.acastipharma.com




Read more...

Ratios

vs
industry
vs
history
PE Ratio 12.81
APO's PE Ratio is ranked higher than
54% of the 1112 Companies
in the Global Asset Management industry.

( Industry Median: 12.73 vs. APO: 12.81 )
Ranked among companies with meaningful PE Ratio only.
APO' s PE Ratio Range Over the Past 10 Years
Min: 5.93  Med: 14.21 Max: 59
Current: 12.81
5.93
59
Forward PE Ratio 11.95
APO's Forward PE Ratio is ranked higher than
79% of the 208 Companies
in the Global Asset Management industry.

( Industry Median: 13.14 vs. APO: 11.95 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 12.81
APO's PE Ratio without NRI is ranked higher than
55% of the 1121 Companies
in the Global Asset Management industry.

( Industry Median: 12.98 vs. APO: 12.81 )
Ranked among companies with meaningful PE Ratio without NRI only.
APO' s PE Ratio without NRI Range Over the Past 10 Years
Min: 5.93  Med: 14.21 Max: 59
Current: 12.81
5.93
59
Price-to-Owner-Earnings 43.25
APO's Price-to-Owner-Earnings is ranked lower than
91% of the 333 Companies
in the Global Asset Management industry.

( Industry Median: 12.44 vs. APO: 43.25 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
APO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.08  Med: 7.59 Max: 43.25
Current: 43.25
4.08
43.25
PB Ratio 12.85
APO's PB Ratio is ranked lower than
98% of the 1500 Companies
in the Global Asset Management industry.

( Industry Median: 1.00 vs. APO: 12.85 )
Ranked among companies with meaningful PB Ratio only.
APO' s PB Ratio Range Over the Past 10 Years
Min: 1.55  Med: 5.31 Max: 12.85
Current: 12.85
1.55
12.85
PS Ratio 2.50
APO's PS Ratio is ranked higher than
80% of the 1199 Companies
in the Global Asset Management industry.

( Industry Median: 6.49 vs. APO: 2.50 )
Ranked among companies with meaningful PS Ratio only.
APO' s PS Ratio Range Over the Past 10 Years
Min: 0.44  Med: 2.07 Max: 11.2
Current: 2.5
0.44
11.2
Price-to-Free-Cash-Flow 8.08
APO's Price-to-Free-Cash-Flow is ranked higher than
74% of the 362 Companies
in the Global Asset Management industry.

( Industry Median: 15.43 vs. APO: 8.08 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
APO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 1.37  Med: 4.95 Max: 23.11
Current: 8.08
1.37
23.11
Price-to-Operating-Cash-Flow 8.00
APO's Price-to-Operating-Cash-Flow is ranked higher than
74% of the 772 Companies
in the Global Asset Management industry.

( Industry Median: 16.86 vs. APO: 8.00 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
APO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.37  Med: 4.87 Max: 22.42
Current: 8
1.37
22.42
EV-to-EBIT 9.68
APO's EV-to-EBIT is ranked higher than
62% of the 1295 Companies
in the Global Asset Management industry.

( Industry Median: 11.90 vs. APO: 9.68 )
Ranked among companies with meaningful EV-to-EBIT only.
APO' s EV-to-EBIT Range Over the Past 10 Years
Min: -2.1  Med: 1.4 Max: 12.5
Current: 9.68
-2.1
12.5
EV-to-EBITDA 9.52
APO's EV-to-EBITDA is ranked higher than
61% of the 1333 Companies
in the Global Asset Management industry.

( Industry Median: 11.65 vs. APO: 9.52 )
Ranked among companies with meaningful EV-to-EBITDA only.
APO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2.1  Med: 1.4 Max: 10.8
Current: 9.52
-2.1
10.8
Current Ratio 3.24
APO's Current Ratio is ranked lower than
56% of the 956 Companies
in the Global Asset Management industry.

( Industry Median: 4.32 vs. APO: 3.24 )
Ranked among companies with meaningful Current Ratio only.
APO' s Current Ratio Range Over the Past 10 Years
Min: 1.47  Med: 3.78 Max: 42.98
Current: 3.24
1.47
42.98
Quick Ratio 3.24
APO's Quick Ratio is ranked lower than
56% of the 956 Companies
in the Global Asset Management industry.

( Industry Median: 4.24 vs. APO: 3.24 )
Ranked among companies with meaningful Quick Ratio only.
APO' s Quick Ratio Range Over the Past 10 Years
Min: 1.47  Med: 3.78 Max: 42.98
Current: 3.24
1.47
42.98
Days Sales Outstanding 280.08
APO's Days Sales Outstanding is ranked lower than
91% of the 486 Companies
in the Global Asset Management industry.

( Industry Median: 40.24 vs. APO: 280.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
APO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 233.16  Med: 280.08 Max: 2223.03
Current: 280.08
233.16
2223.03

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 5.30
APO's Dividend Yield % is ranked higher than
71% of the 1488 Companies
in the Global Asset Management industry.

( Industry Median: 4.04 vs. APO: 5.30 )
Ranked among companies with meaningful Dividend Yield % only.
APO' s Dividend Yield % Range Over the Past 10 Years
Min: 0.39  Med: 3.09 Max: 14.65
Current: 5.3
0.39
14.65
Dividend Payout Ratio 0.59
APO's Dividend Payout Ratio is ranked lower than
53% of the 900 Companies
in the Global Asset Management industry.

( Industry Median: 0.55 vs. APO: 0.59 )
Ranked among companies with meaningful Dividend Payout Ratio only.
APO' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.07  Med: 0.59 Max: 3.21
Current: 0.59
0.07
3.21
3-Year Dividend Growth Rate 64.70
APO's 3-Year Dividend Growth Rate is ranked higher than
97% of the 651 Companies
in the Global Asset Management industry.

( Industry Median: 2.60 vs. APO: 64.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
APO' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 91.3
Current: 64.7
0
91.3
Forward Dividend Yield % 6.72
APO's Forward Dividend Yield % is ranked higher than
79% of the 1408 Companies
in the Global Asset Management industry.

( Industry Median: 4.36 vs. APO: 6.72 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 35.17
APO's 5-Year Yield-on-Cost % is ranked higher than
96% of the 1743 Companies
in the Global Asset Management industry.

( Industry Median: 6.87 vs. APO: 35.17 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
APO' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.58  Med: 20.43 Max: 96.85
Current: 35.17
2.58
96.85
3-Year Average Share Buyback Ratio -2.20
APO's 3-Year Average Share Buyback Ratio is ranked lower than
55% of the 868 Companies
in the Global Asset Management industry.

( Industry Median: -1.30 vs. APO: -2.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
APO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -57  Med: -2.1 Max: 0
Current: -2.2
-57
0

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 14.83
APO's Price-to-Tangible-Book is ranked lower than
97% of the 1434 Companies
in the Global Asset Management industry.

( Industry Median: 1.01 vs. APO: 14.83 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
APO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.59  Med: 6.5 Max: 11.34
Current: 14.83
2.59
11.34
Price-to-Intrinsic-Value-Projected-FCF 0.91
APO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
70% of the 434 Companies
in the Global Asset Management industry.

( Industry Median: 1.07 vs. APO: 0.91 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
APO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.52  Med: 0.67 Max: 0.81
Current: 0.91
0.52
0.81
Price-to-Median-PS-Value 1.20
APO's Price-to-Median-PS-Value is ranked lower than
63% of the 819 Companies
in the Global Asset Management industry.

( Industry Median: 1.01 vs. APO: 1.20 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
APO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.38  Med: 0.99 Max: 1.95
Current: 1.2
0.38
1.95
Price-to-Graham-Number 2.89
APO's Price-to-Graham-Number is ranked lower than
90% of the 947 Companies
in the Global Asset Management industry.

( Industry Median: 0.82 vs. APO: 2.89 )
Ranked among companies with meaningful Price-to-Graham-Number only.
APO' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.99  Med: 2.09 Max: 3.54
Current: 2.89
0.99
3.54
Earnings Yield (Greenblatt) % 10.33
APO's Earnings Yield (Greenblatt) % is ranked higher than
73% of the 1804 Companies
in the Global Asset Management industry.

( Industry Median: 5.13 vs. APO: 10.33 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
APO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 8  Med: 42.2 Max: 7426.1
Current: 10.33
8
7426.1

More Statistics

Revenue (TTM) (Mil) $1,970
EPS (TTM) $ 2.09
Beta1.02
Short Percentage of Float0.97%
52-Week Range $14.25 - 27.78
Shares Outstanding (Mil)402.60

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 2,025 2,458 2,843
EPS ($) 2.23 2.63 3.04
EPS without NRI ($) 2.23 2.63 3.04
EPS Growth Rate
(Future 3Y To 5Y Estimate)
-0.37%
Dividends per Share ($) 1.55 2.00 2.68
» More Articles for APO

Headlines

Articles On GuruFocus.com
Tiger Global Management Invests in Apollo Global Management Apr 04 2017 
Presidio, Inc. (Nasdaq: PSDO) to Ring The Nasdaq Stock Market Opening Bell in Celebration of its IPO Mar 10 2017 
Presidio, Inc. Announces Pricing of Initial Public Offering Mar 09 2017 
Affiliates of Apollo and HGM Agree to Combine Novitex and SourceHOV with Quinpario Acquisition Corp. Feb 22 2017 
Alan Fournier Takes Stake in the New Twinkie Maker Hostess Aug 01 2016 
The Carlyle Group Is a Screaming Buy Jul 29 2016 
Acasti Announces Grant of Stock Options May 30 2016 
Acasti Announces Fourth Quarter and Fiscal Year Results May 25 2016 
Jan D'Alvise Appointed President & CEO of Acasti Pharma May 12 2016 
Nasdaq Grants Acasti Cure Period to Regain Compliance with Audit Committee Membership Requirements Mar 25 2016 

More From Other Websites
Edited Transcript of APO earnings conference call or presentation 28-Apr-17 2:00pm GMT Apr 30 2017
Intermediate Co. LLC -- Moody's assigns first time B3 CFR to Exela in connection with reverse IPO... Apr 28 2017
[$$] Apollo Global Swings to Profit on Portfolio Strength Apr 28 2017
Apollo Global Management, LLC Reports First Quarter 2017 Results Apr 28 2017
[$$] Private Equity Attracts New Activist Believers Apr 27 2017
Investment Managers' Earnings on Apr 28: BEN, APO, VRTS Apr 27 2017
[$$] Wall Street’s New Problem: When Fund Titans Invest on the Side Apr 26 2017
Private Equity Weighs Nuclear Option: Westinghouse Electric Apr 26 2017
Massive Institutional Purchases Highlight Insider Buying: Wells Fargo, Apollo Global, Pulse... Apr 22 2017
Apollo Boosts Fund's Stock Allowance for ‘Diamonds in the Rough’ Apr 21 2017
NCL Corporation Ltd. -- Moody's changes NCL's outlook to positive Apr 20 2017
Wells Fargo Among 5 Stocks Insiders Are Loading Up On Apr 19 2017
[$$] Venoco Returns to Bankruptcy Court Despite 'Great Hopes' Apr 18 2017
Mood Media Corporation -- Moody's downgrades Mood Media's PDR to Caa3-PD, other ratings remain... Apr 18 2017
What if U.S. Alt Asset Managers Converted to C-Corps? Apr 17 2017
[$$] Oil Driller Venoco Files Chapter 22 Bankruptcy Apr 17 2017
Fresh Market, Inc. (The) -- Moody's downgrades Fresh Market to B3 Apr 14 2017
A Bankruptcy That Wrecked Global Prospects Of American Nuclear Energy Apr 13 2017
[$$] Apollo Sets Sights on $22.5 Billion for Newest Distressed Fund Apr 13 2017
5 Stocks Insiders Love Right Now Apr 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)